Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 3

Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

November 28, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Now Viewing

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

How do you take into account your patient’s preference and/or lifestyle when selecting from these treatment options? What is your approach to shared decision-making?
Is there an optimal sequence in which you give these potential treatment options? Dr Fakih, please also feel free to share your clinical perspective on treatment sequencing.